EASL/AASLD Endpoint Meeting virtual
EASL–AASLD HCC Endpoints meeting was held digitally on 28th – 30th October 2021.
This 2-day virtual event was organised and managed by Congrex. This conference held discussions, lectures, and talks around clinical trial design and endpoints, immune-based therapies, HCC prevention, patient-reported outcomes and molecular profiling and classification
The congress was aimed at Clinicians and scientists involved in the clinical management or investigation of patients with HCC (hepatocellular carcinoma).
The total number of virtual attendees at the EASL–AASLD HCC Endpoints meeting reached over 150.
